Wilms
58 programs · 53 companies
Programs
58
Companies
53
Trials
56
MOAs
37
CD47iPRMT5iMeniniFGFRiIL-17iRAS(ON)iBTKiPD-L1iAnti-TauSGLT2i
Drugs
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Cevizanubrutinib | Preclinical | FcRn | ||
| LLY-6079 | Phase 2 | MDM2 | ||
| Ivorelsin | Approved | JAK1 | ||
| LLY-1956 | Phase 1/2 | BCMA | ||
| SNY-2289 | Phase 2/3 | CD38 | ||
| SNY-9073 | Phase 2 | B7-H3 | ||
| TAK-2403 | Phase 2 | WEE1 | ||
| Nirafutibatinib | Phase 2 | WRN | ||
| REG-2172 | Phase 1/2 | PCSK9 | ||
| Tixarelsin | Phase 1 | ALK | ||
| Motazanubrutinib | Preclinical | CD38 | ||
| ALM-8546 | Phase 1/2 | MDM2 | ||
| ETN-4807 | Phase 1/2 | APOC3 | ||
| Rimanaritide | Phase 1 | CDK4/6 | ||
| Voxafotisoran | Phase 1 | CDK2 | ||
| Lisosotorasib | NDA/BLA | Menin | ||
| IPN-4133 | NDA/BLA | PI3Kα | ||
| Fixarapivir | Preclinical | CD3 | ||
| Gozebrutinib | Approved | Tau | ||
| NIA-IIT-852 | NDA/BLA | PCSK9 | ||
| Rilunaritide | Phase 1 | ALK | ||
| Tirasertib | Phase 1/2 | BCMA | ||
| Pexasotorasib | Phase 1 | IL-13 | ||
| Pexaderotide | Phase 1/2 | APOC3 | ||
| PRQ-8250 | Phase 2/3 | RET | ||
| ACO-697 | Phase 1/2 | TIM-3 | ||
| CN-8014 | Phase 2/3 | Aβ | ||
| Gelirasimod | Phase 3 | TNFα | ||
| Voxafotisoran | Phase 2 | MDM2 | ||
| Ribocilimab | Phase 3 | CDK4/6 | ||
| CLO-7126 | Preclinical | PARP | ||
| ANR-8751 | Phase 2/3 | CDK2 | ||
| Surazumab | Preclinical | FLT3 | ||
| Tirazasiran | Phase 1/2 | BET | ||
| 255-7731 | Phase 1 | EZH2 | ||
| ASK-6688 | NDA/BLA | SGLT2 | ||
| Zanutuximab | Phase 2 | TYK2 | ||
| IVE-1720 | Phase 2/3 | MALT1 | ||
| RYT-8232 | Phase 2/3 | MET | ||
| Datomavacamten | Approved | BTK | ||
| CAR-9866 | Phase 3 | CD38 | ||
| Nidainavolisib | Approved | Menin | ||
| Bemazanubrutinib | Approved | AuroraA | ||
| DPH-273 | NDA/BLA | BET | ||
| TRI-2500 | Phase 1/2 | AHR | ||
| BEL-9345 | NDA/BLA | CD38 | ||
| FER-3003 | Phase 1/2 | FXIa | ||
| ESC-2972 | Phase 2 | EGFR | ||
| Mavuderotide | Approved | CD47 | ||
| INS-860 | Phase 2 | EZH2 | ||
| PRO-4197 | Approved | SHP2 | ||
| Fixalucimab | Preclinical | TYK2 | ||
| ROY-IIT-520 | Phase 2/3 | RET | ||
| CAM-IIT-713 | Phase 1 | IL-23 | ||
| CAM-IIT-544 | NDA/BLA | EZH2 | ||
| HOS-IIT-667 | Phase 3 | CFTR | ||
| RAB-IIT-788 | NDA/BLA | CDK2 | ||
| Tixasotorasib | NDA/BLA | CD19 |
Trials (56)
| NCT | Drug | Phase | Status |
|---|---|---|---|
| NCT03536299 | Cevizanubrutinib | Preclinical | Recruiting |
| NCT07526932 | LLY-6079 | Phase 2 | Active |
| NCT04912450 | SNY-2289 | Phase 2/3 | Recruiting |
| NCT07281983 | SNY-9073 | Phase 2 | Active |
| NCT04024495 | Nirafutibatinib | Phase 2 | Active |
| NCT06335883 | REG-2172 | Phase 1/2 | Recruiting |
| NCT08293709 | REG-2172 | Phase 1/2 | Recruiting |
| NCT08793201 | Tixarelsin | Phase 1 | Not yet recr... |
| NCT07583988 | ETN-4807 | Phase 1/2 | Not yet recr... |
| NCT03694198 | Rimanaritide | Phase 1 | Recruiting |
| NCT06881630 | Rimanaritide | Phase 1 | Active |
| NCT07839156 | Lisosotorasib | NDA/BLA | Not yet recr... |
| NCT08291233 | Lisosotorasib | NDA/BLA | Recruiting |
| NCT06326452 | IPN-4133 | NDA/BLA | Recruiting |
| NCT03815197 | IPN-4133 | NDA/BLA | Active |
| NCT07488696 | Gozebrutinib | Approved | Active |
| NCT06232980 | NIA-IIT-852 | NDA/BLA | Completed |
| NCT07282846 | Rilunaritide | Phase 1 | Active |
| NCT05750723 | Pexasotorasib | Phase 1 | Not yet recr... |
| NCT07994556 | ACO-697 | Phase 1/2 | Not yet recr... |